AIM at Melanoma Earns a Four-Star Rating From Charity Navigator
December 21, 2022 (Richmond, California) AIM at Melanoma is proud to announce that its strong financial health and ongoing accountability…
12/23/2022
AIM at Melanoma Earns a Four-Star Rating From Charity Navigator
December 21, 2022 (Richmond, California) AIM at Melanoma is proud to announce that its strong financial health and ongoing accountability…
|
11/16/2022
How’s it Growing?
AIM at Melanoma is honored to have been selected by the Matthew Hill Foundation to be a benefitting charity in…
|
11/16/2022
The Importance of Having a Will
It started with a 13-year melanoma survivor letting us know that he had put us in his will. Jeff Berg,…
|
10/25/2022
Things Are About To Get Hairy!
As the name suggests, No-Shave November is an annual event during which participants forgo shaving and other hair trimming in…
10/12/2022
Create a Legacy with AIM
October 17th – 23rd, 2022 is National Estate Planning Awareness Week Creating a legacy gift that supports melanoma research in…
|
03/21/2022
La vida después de la pérdida: La vida de Lisa Huntley ha cerrado el círculo
por Mara Klecker Lisa Huntley recuerda que en 1994 salió del hospital sin su marido, Grant, y pensó...
|
|
01/26/2022
Hágase miembro del gremio de simpatizantes
"¿Cómo puedo ayudar?" Afortunadamente para AIM, son muchos los que nos llaman o escriben y nos hacen esta pregunta. Y...
|
01/26/2022
Caminando para conquistar el melanoma: los trabajadores milagrosos de Mike
Por Mara Klecker Incluso cuando la pandemia obligó a que la Caminata/Carrera del Melanoma KDB 5k fuera virtual en 2020, Mike's Miracle...
|
|
12/09/2021
Un sincero agradecimiento a nuestros patrocinadores de la subasta
¡Gracias, gracias, gracias a los donantes de nuestra subasta online 2021! La Gala de la Gratitud-AIM en Melanoma...
|
12/07/2021
En memoria de una mujer, una tradición ayuda a crear una comunidad de apoyo
por Mara Klecker La idea de una marcha para recaudar fondos y concienciar sobre el melanoma se le ocurrió a Tricia Edwards...
|
|
Entradas recientes
Mar. 14, 2023
Transformation after Trauma
Feb. 28, 2023
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
Feb. 07, 2023
Functional Nutrition for Cancer Survivors
Jan. 27, 2023
Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?
Jan. 26, 2023